Here is the design of a clinical trial:

Official Title: Deprescribing: a Portrait and Out-comes of the Reduction of Polypharmacy in Portugal

Included conditions:
- Polypharmacy
- Deprescriptions

Study Armgroups:
- {'label': 'Elderly Enablement', 'type': 'EXPERIMENTAL', 'description': 'The investigators will give enablement tools and talks with their GPs about how to issue the problem of polypharmacy.', 'interventionNames': ['Behavioral: Elderly Enablement']}
- {'label': 'Control', 'type': 'NO_INTERVENTION', 'description': 'This will be the control group.'}

Interventions:
- {'type': 'BEHAVIORAL', 'name': 'Elderly Enablement', 'description': 'The information given in this group will result from the knowledge obtained in previous phase of the study in the shape of small leaflets and other information materials to be made according to the best practice, to be given and remembered at scheduled times to the intervention group', 'armGroupLabels': ['Elderly Enablement']}

Primary Outcomes:
- {'measure': 'Willingness to be deprescribed after the intervention with open-questions', 'description': 'Assess the enablement of older adults while being Deprescribed in the rise of Willingness to be Deprescribed with two open-questions (one to assess the facilitators and the other to assess the barriers) together with their perception of medication (Beliefs about Medicines Questionnaire).', 'timeFrame': 'six months'}

Please estimate the sample size based on the assumption: 
A 95% confidence interval (CI) and a maximum precision error of 5% are considered. A dropout rate of around 25% is assumed.
Sample size
          Since the prevalence of polypharmacy in older adults in Centre of Portugal is unknown, we will consider that it is around 60% of the older adultsâ population in this region (around 520 000). So we need at least 380 patients with polypharmacy, to obtain a sample with a 95%âCI and a maximum precision error of 5%. However, assuming a dropout rate of around 25%, we will increase the requiredÂ sample by 25% in order to compensate for dropouts, so we will need at least 474 patients with polypharmacy. Then we will create two groups with a minimum of 237 patients each (one will be the intervention group and the other the control).